Update on renal disease for the dental practitioner

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 92, Issue 1, 2001, Pages 9-16

  Kerr, A Ross ^a  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTEREMIA; CHRONIC KIDNEY FAILURE; DENTAL CARE; DISEASE COURSE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNE DEFICIENCY; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHARMACOKINETICS; PHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BACTEREMIA; DENTAL CARE FOR CHRONICALLY ILL; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY; KIDNEY FAILURE, CHRONIC; PHARMACOKINETICS; RISK ASSESSMENT; RISK FACTORS;

EID: 0035403672     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2001.115976     Document Type: Article

References (26)

1. Rhodus NL, Little JW. Dental management of the renal transplant patient. Compendium 1993;14:518-24, 526, 528.
2. Jones CA, McQullan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, et al. Serum creatinine levels in the United States population: Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 1998;32: 992-9.
3. US Renal Data System, USRDS 2000 Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda (MD). Table 1.
4. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal disease: a meta-analysis. Ann Intern Med 1996;124:627-32.
5. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997;127:337-45.
6. Mailloux LU, Haley WE. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998;32:705-19.
7. Venkatesan J, Henrich WL. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Semin Nephrol 1997;17:257-69.
8. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997;57:1678-95.
9. Werner CW, Saad TF. Prophylactic antibiotic therapy prior to dental treatment for patients with end-stage renal disease. Spec Care Dentist 1999;19:106-11.
10. Baglin A, Hanslik T, Vaillant JN, Boulard JC, Moulonguet-Doleris L, Prinseau J. Severe valvular heart disease in patients on chronic dialysis. A five-year multicenter French survey. Ann Med Interne (Paris) 1997:148:521-6.
11. Naugle K, Darby ML, Bauman DB, Lineberger LT, Powers R. The oral health status of individuals on renal dialysis. Ann Periodont 1998:3;197-205.
12. Lentino JR, Baddour LM, Wray M, Wong ES, Yu VL. Staphylococcus aureus and other bacteremias in hemodialysis patients: antibiotic therapy and surgical removal of access site. Infection 2000;28:355-60.
13. McCarthy JT, Steckelberg JM. Infective endocarditis in patients receiving long-term hemodialysis. Mayo Clin Proc 2000;75: 1008-14.
14. Opatry K. Hemostasis disorders in chronic renal failure. Kidney Intl 1997;52(Suppl 62):87-9.
15. Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000;53(Suppl 1):S2-8.
16. Valderrabano F. Recombinant erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant 1997;12(Suppl 1):2-9.
17. Aronoff GR. Drug prescribing in renal failure: dosing guidelines for adults. 4th ed. Philadelphia: American College of Physicians; 1999. p. 15-7.
18. Grabe DW. Drug-related problems in the end-stage renal disease population. Medscape Pharmacists 2000. http://:www.medscape. com/pharmacists/Renal Disease.
19. Henrich WL, Agodoa LE, Barrett B, Bennett WM, Blantz RC, Buckalew VM Jr, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation From an ad hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996:27;162-5.
20. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: Summary and recommendations. Am J Kidney Dis 1996;28(Suppl 1):S56-62.
21. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000:35;937-40.
22. Tominaga Y, Johansson H, Johansson H, Takagi H. Secondary hyperparathyroidism: pathophysiology, histopathology, and medical and surgical management. Surg Today 1997;27: 787-92.
23. Mucsi I, Hercz G. Adynamic bone disease: Pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens 1997;7:356-61.
24. Damm DD, Neville BW, McKenna S, Jones AC, Freedman PD, Anderson WR, et al. Macrognathia of renal osteodystrophy in dialysis patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:489-95.
25. Roberts WE, Simmons KE, Garetto LP, DeCastro RA. Bone physiology and metabolism in dental implantology: risk factors for osteoporosis and other metabolic bone diseases. Implant Dent 1992;1:11-21.
26. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Chang HR. Decreased salivary function in patients with end-stage renal disease requiring hemodialysis. Am J Kidney Dis 2000;36:1110-4.